We are live on ! Find out more
ADMS

Adamas Pharmaceuticals
ADMS

Delisted

ADMS was delisted on the 23rd of November, 2021.

Back to rankings

81 hedge funds and large institutions have $273M invested in Adamas Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 27 increasing their positions, 24 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 24

12% more capital invested

Capital invested by funds: $243M → $273M (+$29.5M)

4% less funds holding

Funds holding: 84 → 81 (-3)

30% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 10

50% less funds holding in top 10

Funds holding in top 10: 6 → 3 (-3)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $358K

Holders
81
Holders Change
-3
Holders Change %
-3.57%
% of All Funds
2.16%
Holding in Top 10
3
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-50%
% of All Funds
0.08%
New
7
Increased
27
Reduced
24
Closed
10
Calls
–
Puts
$358K
Net Calls
-$358K
Net Calls Change
-$26K

Top Buyers

Rank Fund Capital Flow
1
BS
Bow Street
New York
+$10.1M
2
GPP
Great Point Partners
Connecticut
+$7.48M
3
Millennium Management
Millennium Management
New York
+$2.44M
4
BWCA
Brenner West Capital Advisors
New York
+$2.31M
5
NC
Nexthera Capital
New York
+$1.53M

Top Sellers

Rank Fund Capital Flow
1
CPH
C Partners Holding
Switzerland
-$8.78M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.47M
3
IHM
Iguana Healthcare Management
New York
-$1.51M
4
SM
Sabby Management
Florida
-$1.05M
5
TC
TFS Capital
Pennsylvania
-$943K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$44.9M -$2.47M -162,500 -6%
GPP
2
Great Point Partners
Connecticut
$42.7M +$7.48M +492,252 +23%
BWCA
3
Brenner West Capital Advisors
New York
$19.2M +$2.31M +152,275 +15%
BS
4
Bow Street
New York
$18.9M +$10.1M +666,275 +137%
BFA
5
BlackRock Fund Advisors
California
$12.4M +$802K +52,736 +7%
Millennium Management
6
Millennium Management
New York
$11.8M +$2.44M +160,806 +29%
AllianceBernstein
7
AllianceBernstein
Tennessee
$11.5M +$712K +46,841 +7%
Vanguard Group
8
Vanguard Group
Pennsylvania
$10.2M +$76.9K +5,056 +0.8%
EMFAT
9
Emerald Mutual Fund Advisers Trust
Pennsylvania
$9.38M +$181K +11,910 +2%
OTPPB
10
Ontario Teachers' Pension Plan Board
Ontario, Canada
$8.99M – – –
EA
11
Emerald Advisers
Pennsylvania
$8.28M -$86.9K -5,720 -1%
BIT
12
BlackRock Institutional Trust
California
$4.83M +$389K +25,613 +10%
NC
13
Nexthera Capital
New York
$4.57M +$1.53M +100,500 +56%
SFM
14
Sphera Funds Management
Israel
$4.43M – – –
OM
15
Opaleye Management
Massachusetts
$4.1M -$760K -50,000 -17%
State Street
16
State Street
Massachusetts
$3.98M +$270K +17,754 +8%
BOS
17
Bingham Osborn & Scarborough
California
$3.85M – – –
GPCM
18
Granite Point Capital Management
Massachusetts
$3.68M – – –
Northern Trust
19
Northern Trust
Illinois
$3.16M +$41.8K +2,753 +1%
Fidelity International
20
Fidelity International
Bermuda
$2.96M – – –
BBA
21
Baker Bros. Advisors
New York
$2.83M – – –
JP Morgan Chase
22
JP Morgan Chase
New York
$2.68M +$116K +7,651 +5%
WSA
23
Wall Street Associates
California
$2.37M +$290K +19,100 +15%
Point72 Asset Management
24
Point72 Asset Management
Connecticut
$2.14M -$201K -13,200 -9%
RPAM
25
Rhenman & Partners Asset Management
Sweden
$2.13M – – –
1
2 3 4

ADMS Hedge Fund Activity: Q3 2016 in Review

81 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q3 2016, worth a combined $273M — up 12% from $243M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of ADMS and 7 opened new positions — a net loss of 3 holders — while 24 trimmed existing stakes and 27 added.

The largest buyer was Bow Street, adding an estimated $10.1M. The largest seller was C Partners Holding, cutting an estimated $8.78M.

  • 81 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q3 2016, down from 84 in Q2 2016.
  • Funds reported $273M of Adamas Pharmaceuticals stock for Q3 2016, up 12% quarter-over-quarter.
  • 7 funds opened new Adamas Pharmaceuticals positions in Q3 2016 and 10 closed out, a net change of -3 holders.
  • The largest Adamas Pharmaceuticals buyer in Q3 2016 was Bow Street, an estimated $10.1M added.
  • The largest Adamas Pharmaceuticals seller in Q3 2016 was C Partners Holding, an estimated $8.78M sold.

Based on aggregated 13F filings for Q3 2016.